Therapeutic trials in the murine model of hereditary tyrosinaemia type I: A progress report

Journal of Inherited Metabolic Disease

Volumn 21, Issue 5, 1998, Pages 518-531

  Grompe, M ^a   Overturf, K ^a   Al Dhalimy, M ^a   Finegold, M ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 NITRO 4 FLUOROMETHYLBENZOYL) 1,3 CYCLOHEXANEDIONE; FUMARYLACETOACETASE; KETONE DERIVATIVE; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL MODEL; CONFERENCE PAPER; ENZYME DEFICIENCY; GENE THERAPY; KNOCKOUT MOUSE; LIVER FAILURE; MOUSE; NONHUMAN; RETROVIRUS; SOUTHERN BLOTTING; TYROSINEMIA;

4-HYDROXYPHENYLPYRUVATE DIOXYGENASE; AMINO ACID METABOLISM, INBORN ERRORS; ANIMALS; CYCLOHEXANONES; ENZYME INHIBITORS; GENE THERAPY; HUMANS; HYDROLASES; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITROBENZOATES; TYROSINE;

EID: 0031869522     PISSN: 01418955     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005462804271     Document Type: Conference Paper

References (57)

1. Agsteribbe E, van Faassen H, Hartog MV, et al (1990) Nucleotide sequence of cDNA encoding human fumarylacetoacetase. Nucleic Acids Res 18: 1887.
2. Bain MD, Purkiss P, Jones M, Bingham P, Stacey TE, Chalmers RA (1990) Dietary treatment eliminates succinylacetone from the urine of a patient with tyrosinemia type I. Eur J Pediatr 149: 637-639.
3. Bird S, Miller NJ, Collins JE, Rice-Evans CA (1995) Plasma antioxidant capacity in two cases of tyrosinaemia type 1: one case treated with NTBC. J Inher Metab Dis 18: 123-126.
4. Demers SI, Tanguay RM (1991a) BqIII RFLP for the human fumarylacetoacetate hydrolase (FAH) gene. Nucleic Acids Res 19: 1965.
5. Demers SI, Tanguay RM (1991b) MspI RFLP in the human fumarylacetoacetate hydrolase (FAH) gene. Nucleic Acids Res 19: 6971.
6. Demers SI, Phaneuf D, Tanguay RM (1991) Taq1 RFLP for the human fumarylacetoacetate hydrolase (FAH) gene. Nucleic Acids Res 19: 1352.
7. Esquivel CO, Mieles L, Marino IR, et al (1989) Liver transplantation for hereditary tyrosinemia in the presence of hepatocellular carcinoma. Transplant Proc 21: 2445-2446.
8. Gabrielli O, Maiorana A, Paris D, et al (1978) Presentation of a case of chronic type 1 tyrosinemia. Diet therapy and clinical outcome. Minerva Pediatr 30: 1329-1334.
9. Gentz J, Lindblad B, Lindstedt S, Levy L, Shasteen W, Zetterstrom R (1967). Dietary treatment in tyrosinemia (tyrosinosis). With a note on the possible recognition of the carrier state. Am J Dis Child 113: 31-37.
10. Giardini O, Cantani A, Kennaway NG, D'Eufemia P (1983) Chronic tyrosinemia associated with 4-hydroxyphenylpyruvate dioxygenase deficiency with acute intermittent ataxia and without visceral and bone involvement. Pediatr Res 27: 25.
11. Gluecksohn-Waelsch S (1979) Genetic control of morphogenetic and biochemical differentiation: lethal albino deletions in the mouse. Cell 16: 225-237.
12. Grenier A, Lescault A (1985) Succinylacetone. In Bergmeyer HU, ed. Methods of Enzymatic Analysis. Weinheim: VCH, 79.
13. Grompe M, Al-Dhalimy M (1993) Mutations of the fumaryl acetoacetate hydrolase gene in four patients with tyrosinemia, type I. Hum Mutat 2: 85-93.
14. Grompe M, Al-Dhalimy M, Finegold M, et al (1993) Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes Dev 7: 2298-2307.
15. Grompe M, St-Louis M, Demers SI, Al-Dhalimy M, Leclerc B, Tanguay RM (1994) A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I. N Engl J Med 331: 353-357.
16. Grompe M, Lindstedt S, Al-Dhalimy M, et al (1995) Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nature Genetics 10: 453-460.
17. Hirakawa DA, Olson LM, Baker DH (1984) Comparative utilization of a crystalline amino acid diet and a methionine fortified casein diet by young rats and mice. Nutr Res 4: 891-895.
18. Holme E, Lindstedt S. (1998) Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). J Inter Metab Dis 21: 507-511.
19. Jehan P, Buchman M, Odievre M (1984) Dietary management of hereditary tyrosinemia. Apropos of 7 cases. Ann Pediatr (Paris) 31: 33-40.
20. Jimenez-Acosta F (1994) Painful plantar callouses and mental retardation. Tyrosinemia type II. Arch Dermatol 130: 507-511.
21. Kelsey G, Schütz G (1993) Lessons from lethal albino mice. Curr Opin Gen Dev 3: 259-264.
22. Klebig ML, Russell LB, Rinchik EM (1992) Murine fumarylacetoacetate hydrolase (Fah) gene is disrupted by a neonatally lethal albino deletion that defines the hepatocyte-specific developmental regulation 1 (hsdr-1) locus. Proc Natl Acad Sci USA 89: 1363-1367.
23. Kvittingen EA, Jellum E, Stokke O, et al (1986) Liver transplantation in a 23-year-old tyrosinaemia patient: effects on the renal tubular dysfunction. J Inher Metab Dis 9: 216-224.
24. Kvittingen EA, Rootwelt H, Brandtzaeg P, Bergan A, Berger R (1993) Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect. J Clin Invest 91: 1816-1821.
25. Kvittingen EA, Rootwelt H, Berger R, Brandtzaeg P (1994) Self-induced correction of the genetic defect in tyrosinemia type I. J Clin Invest 94: 1657-1661.
26. Labelle Y, Phaneuf D, Leclerc B, Tanguay RM (1993a) Characterization of the human fumarylacetoacetate hydrolase gene and identification of a missense mutation abolishing enzymatic activity. Hum Mol Genet 2: 941-946.
27. Labelle Y, Puymirat J, Tanguay RM (1993b) Localization of cells in the rat brain expressing fumarylacetoacetate hydrolase, the deficient enzyme in hereditary tyrosinemia type 1. Biochim Biophys Acta 1180: 250-256.
28. Lindblad B, Lindstedt S, Steen G (1977) On the enzymic defects in hereditary tyrosinemia. Proc Natl Acad Sci USA 74: 4641-4645.
29. Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B (1992) Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340: 813-817.
30. Markowitz D, Goff S, Bank A (1988a) Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167: 400-406.
31. Markowitz D, Goff S, Bank A (1988b) A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol 62: 1120-1124.
32. McLachlin JR, Mittereder N, Daucher MB, Kadan M, Eglitis MA (1993) Factors affecting retroviral vector function and structural integrity. Virology 195: 1-5.
33. Michals K, Matolon R, Wong PW (1978) Dietary treatment of tyrosinemia type I: importance of methionine restriction. J Am Diet Assoc 73: 507-514.
34. Mieles LA, Esquivel CO, Van Thiel DH, et al (1990) Liver transplantation for tyrosinemia. A review of 10 cases from the University of Pittsburgh. Dig Dis Sci 35: 153-157.
35. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215.
36. Mitchell GA, Lambert M, Tanguay RM (1995) Hypertyrosinemia. In Scriver CR, Beaudet AL, Sly W, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th edn. New York: MacGraw-Hill, 1077-1106.
37. Overturf K, Al-Dhalimy M, Tanguay R, et al (1996) Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nature Genetics 12: 266-273.
38. Overturf K, Al-Dhalimy M, Ou CN, et al (1997) Adenovirus-mediated gene therapy in a mouse model of hereditary tyrosinemia type I. Hum Gene Ther 8: 513-521.
39. Pérez-Cerdà C, Merinero B, Sanz P, et al (1995) Liver transplantation in nine Spanish patients with tyrosinaemia type I. J Inher Metab Dis 18: 119-122.
40. Paradis K, Weber A, Seidman EG, et al (1990) Liver transplantation for hereditary tyrosinemia: the Quebec experience. Am J Hum Genet 47: 338-342.
41. Phaneuf D, Labelle Y, Bérubé D, et al (1991) Cloning and expression of the cDNA encoding human fumarylacetoacetate hydrolase, the enzyme deficient in hereditary tyrosinemia: assignment of the gene to chromosome 15. Am J Hum Genet 48: 525-535.
42. Phaneuf D, Lambert M, Laframboise R, Mitchell G, Lettre F, Tanguay RM (1992) Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient. J Clin Invest 90: 1185-1192.
43. Pronicka E, Rowinska E, Bentkowski Z, Zawadzki J, Holme E, Lindstedt S (1996) Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase inhibitor (NTBC). J Inher Metab Dis 19: 234-238.
44. Riudor E, Ribes A, Lloret J, et al (1991) Liver transplantation in two children with tyrosinaemia type I: biochemical aspects. J Inher Metab Dis 14: 281-284.
45. Rootwelt H, Kvittingen EA, Hoie K, et al (1992) The human fumarylacetoacetase gene: characterisation of restriction fragment length polymorphisms and identification of haplotypes in tyrosinemia type 1 and pseudodeficiency. Hum Genet 89: 229-233.
46. Rootwelt H, Chou J, Gahl WA, et al (1994) Two missense mutations causing tyrosinemia type 1 with presence and absence of immunoreactive fumarylacetoacetase. Hum Genet 93: 615-619.
47. Ruppert S, Kelsey G, Schedl A, Schmid E, Thies E, Schütz G (1992) Deficiency of an enzyme of tyrosine metabolism underlies altered gene expression in newborn liver of lethal albino mice. Genes Dev 6: 1430-1443.
48. Salt A, Barnes ND, Rolles K, Calne RY, Clayton PT, Leonard JV (1992) Liver transplantation in tyrosinaemia type 1: the dilemma of timing the operation. Acta Paediatr 81: 449-452.
49. Sambrook J, Fritsch EF, Maniatis T (eds) (1989) Molecular Cloning: A Laboratory Manual. 2nd edn. Cold Spring Harbor: Cold Spring Harbor Laboratory Press.
50. Sokal EM, Bustos R, Van HF, Otte JB (1992) Liver transplantation for hereditary tyrosinemia - early transplantation following the patient's stabilization. Transplantation 54: 937-939.
51. St-Louis M, Leclerc B, Laine J, Salo MK, Holmberg C, Tanguay RM (1994) Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I. Hum Mol Genet 3: 69-72.
52. Suzuki Y, Konda M, Imai I, Imamura H, Shimao S, Okaka T (1987) Effect of dietary treatment on the renal tubular function in a patient with hereditary tyrosinemia. Int J Pediatr Nephrol 8: 171-176.
53. Tada K, Wada Y, Yazaki N, Yokoyama T, Nakagawa H (1968) Dietary treatment of infantile tyrosinemia. Tohoku J Exp Med 95: 337-344.
54. Tanguay RM, Valet JP, Lescault A, et al (1990) Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I). Am J Hum Genet 47: 308-316.
55. Timmers C, Grompe M (1996) Six novel mutations in the fumarylacetoacetate hydrolase gene of patients with hereditary tyrosinemia type I. Hum Mutat 7: 367-369.
56. van-Spronsen FJ, Smit GP, Wijburg FA, Thomasse Y, Visser G, Heymans HS (1995) Tyrosinaemia type I: considerations of treatment strategy and experiences with risk assessment, diet and transplantation. J Inher Metab Dis 18: 111-114.
57. Vrancken Peeters MJ, Lieber A, Perkins J, Kay MA (1996) Method for multiple portal vein infusions in mice: quantitation of adenovirus-mediated hepatic gene transfer. Biotechniques 20: 278-285.